Converge Bio Inc.

CLAYMONT, DE · Founded 2024 · CIK 0002131104 · Biotech · Private

GenAI platform for drug discovery, molecule design, and manufacturing optimization

converge-bio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$25M
1 Form D · Apr 2026
5 months since last filing
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$25,000,000
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2001NiKang Therapeutics—$200M
2002Regulonix——
2003FORMATION VENTURE ENGINEERING FOUNDRY INC——
2004Converge Bio Inc.—$25M
2005ALPHA YOUNG LLC——
2006Dispatch Biotherapeutics——
2007OROX BIOSCIENCES, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 5 related persons
  • Dov GertzDirector · Executive Officer
  • Andrew HedinDirector
  • Oded KalevDirector · Executive Officer
  • Shahar TzafrirDirector
  • Iddo WeinerExecutive Officer

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.